MAVENIR
21.5.2021 05:02:10 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that it’s working with National Telecom Public Company Limited (NT), a state-owned telecommunications company, 5GCT , a local partner specialized in delivering end-to-end 5G Smart Cities and Cisco Systems (Thailand), a leading networking company, to launch the first 5G Open RAN Smart City in Ban Chang, Thailand.
The launch of the 5G Smart City creates synergies between public and private sectors for a fully functional smart city. The city of Ban Chang, is connected to a motorway linking Thailand’s two largest cities: Pattaya and Bangkok. The location is within close proximity to U-Tapao International Airport, Map Ta Phut Industrial Zone and the new master planned Ban Chang Smart City that are strategically important infrastructure for the Digital Economy in Thailand and the Eastern Economic Corridor (EEC). These characteristics make Ban Chang the perfect city to take advantage of 5G use cases across industrial robots, factory automation, remote telemedicine, aviation, logistics and agriculture. Industry leaders are terming the development the ‘Silicon Beach ’ of Asia.
The Ban Chang Smart City 5G Private Network operates on Millimeter wave (mmWave) spectrum, spectrum which is ideally suited for a network operating Internet of Thing (IoT) sensors, drones and smart poles, all applications which require fast data uplink to the core for realtime analysis and city management.
Mavenir provided a cloud-native, open architecture-based Private Network solution that enabled TOT1 to reach the promise of 5G. The software-based platform enabled the transformation of the mobile communication private network into a completely virtualized environment, where devices, applications, and services run on an automated network using open architecture, containers, and artificial intelligence (AI). Mavenir’s end-to-end 5G Open RAN, Millimeter wave (mmWave) radios and 5G Core with Open API technology standards, in-sync with the cloud-native solutions supporting private On-Premise applications delivers Smart City concepts such as real-time diagnostics of traffic, public safety, digital signage and sensitive environmental conditions.
TOT’s IP transport infrastructure vendor and a key Mavenir technology partner, Cisco, provided switching hardware and application services to enable the ‘smart’ components of the 5G solution.
Mavenir’s Aniruddho Basu, GM of its Emerging Business Unit , said “We are proud to be part of this ambitious 5G project which sees a whole city connected on a series of 5G applications running in parallel. Connectivity is at the heart of this deployment - connecting people, communities, government services, and private sector services through local government data combined with new data acquired through Internet of Things (IOT), sensors, drones, and external collected data, to fully analyze it for proper city management and citizen knowledge.”
Commenting on the announcement, Shannon Kalayanamitr, Chief Executive Officer at 5GCT , said “At 5GTC, we are driven to strengthen the potential of Thailand through high speed 5G. The partnership with Mavenir as an infrastructure provider enables us to deliver robust, secure and reliable 5G Private Network infrastructure across enterprises, including smart city applications, industry 4.0 applications - automated industry and modern medicine.”
Taweewat Chantaraseno, Managing Director, Thailand & Indochina, Cisco Systems (Thailand), said “We are delighted to be part of the first 5G smart city in Thailand. With the partnership with Mavenir and Cisco Connected Communities Infrastructure (CCI), the host of Smart City can create a single, secure communications network to support all needs that are simpler to deploy and manage from end-to-end visibility, ranging from smart kiosks and outdoor Wi-Fi, to smart street lighting, parking, waste and more. Smart city infrastructure is enabling efficiency, cost reduction and improved living for city occupants and network infrastructure platform helps create these efficiencies.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
1 TOT and CAT Telecom recently merged under National Telecommunications Public Company Limited (NT) a Thai Government Telecom service provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005943/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom